Format

Send to

Choose Destination
Nanomedicine (Lond). 2013 Nov;8(11):1807-13. doi: 10.2217/nnm.12.214. Epub 2013 Apr 23.

Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.

Author information

1
Department of Internal Medicine, University of Nebraska Medical Center, 982055 Nebraska Medical Center, Omaha, NE 68198-2055, USA.

Abstract

AIM:

To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy.

METHODS:

Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups.

RESULTS:

Respondents were 68% male and 53% African-American, with a mean age of 47 years. Overall, 73% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61% with weekly dosing; 72% every 2 weekly; and 84% monthly. In total, 48% indicated that they were very concerned about the possible side effects and 35% were very concerned about needle use.

CONCLUSION:

The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.

PMID:
23611617
PMCID:
PMC3987826
DOI:
10.2217/nnm.12.214
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center